Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | F10 | P00742 | 4/20 | 0.38 |
| ▸ | CNR1 | P21554 | 6/20 | 0.38 |
| ▸ | LSS | P48449 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4941341 | 1.00 | SMO (0.47) | SMOHRH3F10CNR1LSS | |
| SCHEMBL4941338 | 0.84 | SMO (0.47) | SMOHRH3F10CNR1LSS | |
| SCHEMBL4936912 | 0.75 | F10 (0.44) | SMOHRH3F10LSSMAPT | |
| SCHEMBL4936922 | 0.75 | F10 (0.44) | SMOHRH3F10LSSMAPT | |
| Hydrochloric Acid SCHEMBL4941484 | 0.71 | SMO (0.52) | SMOHRH3LSSMAPTSMN1; SMN2 | |
| SCHEMBL4881800 | 0.70 | SMO (0.49) | SMOHRH3F10CNR1LSS | |
| SCHEMBL4938153 | 0.70 | SMO (0.49) | SMOF10CNR1MAPTSMN1; SMN2 | |
| SCHEMBL4932706 | 0.70 | HRH3 (0.56) | SMOHRH3MAPT | |
| SCHEMBL4936809 | 0.70 | EPHX2 (0.37) | SMOHRH3F10SMN1; SMN2 | |
| SCHEMBL4939613 | 0.70 | F10 (0.45) | HRH3F10CNR1LSSMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007008143-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF FACTOR XA | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | claimed |
| US-20080214495-A1 | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214495-A1 | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa | F10, F12, F11 | SMO 1477/4885HRH3 31/4885F10 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.